Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.

Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry. 2001;158(3):360-9. DOI: 10.1176/appi.ajp.158.3.360. PubMed PMID: 11229973.

Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database.

Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang R-H, Nasrallah HA. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry. 2002;63(10):920-30. PubMed PMID: 12416602.

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.

Lindenmayer J-P, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. AJP. 2003;160(2):290-6. DOI: 10.1176/appi.ajp.160.2.290. PubMed PMID: 12562575.

Revisiting the discussion: termination of clozapine treatment due to renal failure.

Woesner ME, Kanofsky JD. Revisiting the discussion: termination of clozapine treatment due to renal failure. J Clin Psychiatry. 2015;76(12):1694. DOI: 10.4088/JCP.15lr10019. PubMed PMID: 26717530.

Dr. Nielsen and colleagues reply.

Nielsen J, Manu P, Kane JM, Correll CU. Dr. Nielsen and colleagues reply. J Clin Psychiatry. 2015;76(12):1694-5. DOI: 10.4088/JCP.15lr10019a. PubMed PMID: 26717531.

Optimizing outcomes in clozapine rechallenge following neutropenia: a cohort analysis.

Meyer N, Gee S, Whiskey E, Taylor D, Mijovic A, Gaughran F, et al. Optimizing outcomes in clozapine rechallenge following neutropenia: a cohort analysis. J Clin Psychiatry. 2015;76(11):e1410-6. DOI: 10.4088/JCP.14m09326. PubMed PMID: 26646037.

Medication for borderline personality disorder: a survey at a secure hospital.

Haw C, Stubbs J. Medication for borderline personality disorder: a survey at a secure hospital. Int J Psychiatry Clin Pract. 2011;15(4):280-5. DOI: 10.3109/13651501.2011.590211. PubMed PMID: 22122000.

Cognition and Plasma Ratio of Clozapine to N-desmethylclozapine in Patients With Clozapine-Resistant Schizophrenia.

Thornton AE, Procyshyn RM, Barr AM, Macewan GW, Honer WG. Cognition and Plasma Ratio of Clozapine to N-desmethylclozapine in Patients With Clozapine-Resistant Schizophrenia. Am J Psychiatry. 2015;172(12):1259. DOI: 10.1176/appi.ajp.2015.15070899. PubMed PMID: 26619773.

Response to Thornton et al.

Rajji TK. Response to Thornton et al. Am J Psychiatry. 2015;172(12):1259-60. DOI: 10.1176/appi.ajp.2015.15070899r. PubMed PMID: 26619774.

Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response.

Conley RR, Tamminga CA, Kelly DL, Richardson CM. Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biol Psychiatry. 1999;46(1):73-7. PubMed PMID: 10394475.